37 results about "Albumin urine" patented technology

The invention relates to a urinary microalbumin (U-mALb) / urinary creatinine (U-Cr) integrated assay bigeminy strip, comprising a sample area and reaction areas. The U-mALb / U-Cr integrated assay bigeminy strip is characterized in that the sample area comprises a diffusion membrane and blood filtering membranes; the reaction areas comprise two detection windows, and the two detection windows can be used for detecting the ratios of the U-mALb and the U-Cr at the same time; the sample area for detecting the U-Cr by adopting a dry chemical method is arranged at the position where the reaction area is positioned, and the reaction area for detecting the U-mALb by using a colloidal gold dry type immune chromatography technology is arranged at a position which is 0.5cm away from the sample area. The different reaction areas contain different reagent pads, and the reagent pads respectively and independently react with corresponding components in urine. Synchronous detection can be realized only by dripping the random urine of a person to be tested into the sample area, so that the U-mALb / U-Cr integrated assay bigeminy strip is very suitable for medical institutions or individuals. By using the U-Cr for correction, the influence, caused by a sampling way and urine volume, on the excretory amount of urinary albumin can be eliminated, so that the U-mALb / U-Cr integrated assay bigeminy strip can provide more accurate evaluation for the albumin excretion rate and has a greater clinical significance for preventing diabetic nephropathy.

The invention relates to a Chinese medicinal preparation for treating kidney diseases and process for preparation, wherein the medicament is prepared from the following Chinese medicinal herbs (by weight portion): red sage root 20-30 parts, barbat skullcap 5-10 parts, safflower 5-10 parts, Japanese felt fern leaf. 5-10 parts, honeysuckle flower 5-10 parts, rheum officinale 10-15 parts, capsule of weeping forsythia 5-10 parts, licorice root 3-6 parts, poria cocos wolf 10-15 parts, panax notoginseng saponins 1-1.5 parts.

Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.

The invention describes and claims the use of vasopeptidase inhibitors of formula (I) for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and / or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.

The invention aims to provide a novel use of penthorum chinense pursh and medicine or health care food prepared from the penthorum chinense pursh, and particularly relates to the novel use of the penthorum chinense pursh and the medicine or health care food prepared from the penthorum chinense pursh in the prevention and treatment of renal albuminuria. Tests show that the penthorum chinense purshhas an effect of reducing urinary proteins of nephropathy. According to the novel use, the application scope of the penthorum chinense pursh is enlarged, and a basis is provided for the clinical application of the penthorum chinense pursh in the prevention and treatment of the renal albuminuria.

The invention relates to a teabag for curing diabetes, which is prepared from 90 to 95 percent of Pu'er Tea and 5 to 10 percent of amino acid concentrated solution. Because the Pu'er tea of the product contains rich trace elements, the Pu'er Tea has positive action on the prevention and reduction of complication of diabetes together with the amino acid, thereby improving and controlling blood sugar and the blood pressure, adjusting the blood-fat and improving the albuminuria.

The invention discloses a Chinese medicinal combination for curing nephritis and edema and the application thereof, composed of Chinese Brake Herb, Jixuecao, Liquoricee Root, Persimmon Leaf, Membranous Milkvetch Root, Plantain Herb, etc. It is to be orally taken, convenient to use, tasting good and easy to be accepted by patients; has functions of nourishing liver and kidney, promoting blood circulation and rmoving blood stasis, and causing diuresis and detumescence, having advantages of good curative effect, short period of treatment, low price, no toxicity and side effect, convenient for patients to take, etc; and it is an ideal effective medicine for patients with acute and chronic nephritis and edema, hematuria, and albuminuria to select.

The invention provides a urinary albumin / urinary creatinine composite quality control product and a production method thereof. The urinary albumin / urinary creatinine composite quality control product comprises the following components: 50-100 mmol / L of a buffer solution, 5-15 g / L of salt, 5-15 g / L of flufenamic acid, 5-15 g / L of dimethyl sulfoxide, 5-15 g / L of a reducing agent, 5-15 g / L of dextran, 5-15 g / L of a defoaming agent; 0.5-1 g / L of a tackifier, 100-200 mg / L of human serum albumin, 10-20 mmol / L of creatinine, and 1 g / L of a preservative. A pH value of the quality control product is 7.2-7.4. The product can be used for evaluating the accuracy of the urinary albumin / urinary creatinine detection reagent based on a microfluidic technology, and plays an important role in guaranteeing the laboratory detection result quality of the urinary albumin / urinary creatinine detection reagent and reducing errors.

The invention discloses treating diabetic nephropathy and microalbuminuria with Chinese herbal medicine Salviae Miltiorrhizae Radix. Including boiling salvia miltiorrhiza to make a water-based extract, and then applying the extract to diabetics or microalbuminuric patients to treat diabetic nephropathy. In addition, it also includes the use of succinic acid inorganic salt extracted from Danshen to the sick body. The present invention also includes measuring the protein level in urine before, during and / or after administering the water-based extract or the inorganic salt of succinic acid to the patient.

The invention relates to the technical field of diabetic nephropathy, in particular to a medicine for treating and preventing diabetic nephropathy, which comprises 10 to 100 mg of tianagliflozin and 10 to 50 mg of DPP24 inhibitor. The medicine prepared by the invention can remarkably reduce the content or expression quantity of blood urea nitrogen, blood creatinine, 24h urine protein, urine protein quantification and transforming growth factor-beta1, remarkably improves the expression quantity of the klotho protein, has a better effect of treating and preventing diabetic nephropathy, can be stored for a long time, and has small toxic and side effects.

The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

The invention discloses a traditional Chinese medicine preparation for treating pneumonia infected with novel coronaviruses. The preparation adopting the formula comprises the components in parts by mass of 15-25 parts of polyporus umbellatus, 15-60 parts of poria cocos, 15-25 parts of rhizoma alismatis, 10-20 parts of talc, 10-20 parts of rhizoma coptidis, 15-25 parts of tree peony bark, 6-30 parts of apricot kernels, 10-20 parts of colla corii asini and 15-25 parts of licorice roots. The traditional Chinese medicine preparation for treating pneumonia infected with novel coronaviruses can realize target effects on human cell surface ACE2 receptors, and can block a way that the novel coronaviruses invade organisms, so that the traditional Chinese medicine preparation has the effects of preventing and treating clinical situation of the novel coronaviruses. The traditional Chinese medicine preparation for treating pneumonia infected with novel coronaviruses has obvious and quick improvement effects on symptoms of fever, dry cough, weakness, chest pain and the like, can reduce blood pressure, alleviate oedematous and has special effects on patients suffering from albuminuria and renalfunction damage through laboratory examination.

After a nephritis patient suffers from nephritis for several years, albumin in a little blood begins to leak into urine, at the moment, albumin leakage is easy to neglect because clinical symptoms arenot significant or the albumin is confused with other albuminuria caused by hypertension and hyperlipaemia, so that the illness state is worsened. But when it is found that other indexes reflecting renal functions, such as [beta]2 microglobulin, [alpha]1 microglobulin, transferrin and immunoglobulin are also obviously increased in urine, the situation confirms that the renal functions already have pathology changes. At present, no other effective methods exist except hormone on treatment, but long-term hormone treatment can cause many side reactions to the patient. If illness course freely develops, more albumin leaks into urine, and kidney damage can be further worsened. Cobra neurotoxin polypeptide molecules can effectively reduce leak of various albumin in urine, control and delay kidney pathologic progress, improve renal functions and have important significance in treatment of the nephritis through restraining autoimmunity inflammatory reactions of the kidney.

The invention discloses a traditional Chinese medicine composition for treating abnormal blood glucose and blood lipid due to diabetes mellitus. The composition is prepared from the following raw materials in parts by weight: 20-30 parts of rhizoma atractylodis, 10-15 parts of herba eupatorii, 8-15 parts of ginseng, 3-20 parts of kudzu vine roots, 15-30 parts of rhizoma polygonati, 12-15 parts of radix ophiopogonis, 12-18 parts of radix sophorae flavescentis, 12-20 parts of coptis chinensis, 15-25 parts of salviae miltiorrhizae, 20-25 parts of semen litchi, 10-20 parts of semen cuscutae, 10-18 parts of rhizoma alismatis, 12-30 parts of astragalus membranaceus, 10-15 parts of dried rehamnnia root, 10-15 parts of cornus officinalis, 10-15 parts of herba epimedii, 10-15 parts of cortex lycii radicis, 10-15 parts of red yeast rice and 10-15 parts of abelmoschus manihot. The invention further discloses a preparation method and an application range of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the effects of nourishing yin, promoting generation of body fluid, tonifying qi, nourishing kidneys, lowering blood glucose and blood lipid, protecting islet B cells of type 2 diabetic patients, reducing insulin resistance, improving insulin sensitivity, reversing renal lesions to a certain extent, improving microalbuminuria, reducing blood lipid and improving lipid metabolism, thereby solving the injury caused by abnormal blood glucose and blood lipid due to diabetes mellitus.

The invention discloses a new application of selepravastatin, namely an application of selepravastatin in preparation of a medicine for treating nephropathy. The application has the advantages that anew medicine for treating the nephropathy is provided, the effect of treating the membranous nephropathy is achieved through the immune effect, and finally animal experiments prove that the selaprivapeptide can reduce total urinary protein, urinary albumin and systolic pressure of membranous nephropathy model animals, so that the selaprivapeptide is a new immune agent and a novel therapeutic meansfor treating the membranous nephropathy.

The invention discloses a method for researching the relationship between HSD17B13 rs72613567 gene variation and renal function injury, and belongs to the technical field of medicine. According to the invention, a patient verified as NAFLD by biopsy is selected as an experimental population, the HSD17B13 genotype of the patient is detected, the glomerular filtration rate (eGFR), urine / serum NGAL and the ratio (u-ACR) of urine albumin to creatinine of the patient are measured, and finally, the relationship between the HSD17B13 rs72613567 genotype and gene variation and renal function damage is determined by multivariate regression analysis. Results show that the HSD17B13 rs72613567 A / - or A / A genotype is significantly related to a relatively low proteinuria risk, but is irrelevant to u-NGAL concentration or eGFR level, so that a novel insight is provided for early renal injury.

The invention provides a Chinese traditional medicine preparation for curing nephritis, which is composed of following materials by weight ratio: asiatic plantain seed 15 to 25, tuckahoe 15 to 25, rhizoma imperatae 15 to 25, elderberry 12 to 18, waxgourd peel 25 to 35, corn silk 70 to 90, red phaseolus bean 25 to 35, eucommia bark 12 to 18, prepared rhizome of adhesive rehmannia 30 to 40, mistletoe 25 to 35, astragalus root 40 to 60. The medicine preparation can prove to have total efficiency ratio of 87.3% for curing the acute / chronic nephritis through watching patients clinical symptom and urokinase protein, urine hematid and kidney function change.

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans.

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing hypertension and diabetic kidney disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes related renal complications, hypertension, albuminuria, Heart Diseases, ESRD, Kidney GFR complications, Vascular Disease, Ventricular Septal Defect, vascular dilation, high blood pressure, congestive heart failure (CHF), post-myocardial infarction (MI).

The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition contains crude drugs of radix dioscorea septemloba / dioscorea hypoglauca, ginseng, radixastragali, radix angelica sinensis, bighead atractylodes rhizomes, cinnamomum cassia bark, aconitum carmichaelii seminal root processed products, cornu cervi pantotrichum, alpinia oxyphylla fruits, lindera aggregata tubers, acorus tatarinowii reizomes and processed gizzard inner walls. The traditional Chinese medicine composition disclosed by the invention can strengthen the middle warmer, benefit qi, warm and recuperate kidney yang, promote urination and remove turbidity, and has favorable treatment effects on albuminuria, and symptoms of renal cell damage and high creatinine caused by nephropathy.

The invention discloses a traditional Chinese medicine composition for treating insulin resistance of type 2 diabetes mellitus and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-60 parts of abelmoschus manihot flowers, 15-60 parts of pyrrosia lingua, 15-60 parts of oldenlandia diffusa, 5-15 parts of coptis chinensis and 15-60 parts of leonurus. The traditional Chinese medicine composition disclosed by the invention has the effects of clearing heat and promoting diuresis as well as dispersing blood stasis and dredging collaterals, and is used for treating insulin resistance and microalbuminuria of type 2 diabetes mellitus. Clinical pharmacodynamic tests show that the traditional Chinese medicine composition has a multi-target treatment function on insulin resistance and microalbuminuria of patients suffering from type 2 diabetes mellitus, and is free of adverse reaction in the testing process; in-vivo pharmacological tests show that the traditional Chinese medicine composition is capable of alleviating insulin resistance of diabetes mellitus, improving structures and functions of foot cells and reducing microalbuminuria; and a novel option is provided for clinical treatment on early kidney injury of type 2 diabetes mellitus with refractory proteinuria as characteristics.

A method for a determining of risk for development of cardiovascular disease by measuring levels of the at least gene of interest is disclosed. The method may identify subjects with moderate albuminuria and diagnosis or predict cardiovascular disease several years before either of these outcomes is detectable by present methodologies.

The invention relates to the technical field of medicines, in particular to a new application of a cephalosporin compound to preparation of a medicine for treating diabetes. The structural formula of the cephalosporin compound is shown in the formula I. Experimental results show that the cephalosporin compound can improve glycometabolism of a mouse with type 2 diabetes, improve insulin sensitivity and improve insulin resistance, and can reduce the blood sugar of the mouse with type 2 diabetes is reduced, and the curative effect of reducing the blood sugar by using the cephalosporin compound is 12.5 times that of metformin. The contents of urine protein, urine creatinine and urea nitrogen in the mouse with type 2 diabetes are reduced, so that the cephalosporin compound can protect the renal function of the mouse with diabetes and treat nephropathy caused by diabetes. The content of triglyceride, low-density lipoprotein cholesterol and total cholesterol in the mouse with type 2 diabetes is reduced, the blood fat level is adjusted, and the lipid metabolism of the mouse with diabetes is improved, so that the cephalosporin compound can be used for treating cardiovascular complications of diabetes. The cephalosporin compound can be clinically popularized and applied.

The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.